Phase I and Pharmacokinetic Trial of Gemcitabine in Patients With Hepatic or Renal Dysfunction: Cancer and Leukemia Group B 9565
- 14 July 2000
- journal article
- clinical trial
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 18 (14) , 2780-2787
- https://doi.org/10.1200/jco.2000.18.14.2780
Abstract
PURPOSE: To ascertain if hepatic or renal dysfunction leads to increased toxicity at a given dose of gemcitabine and to characterize the pharmacokinetics of gemcitabine and its major metabolite in ...Keywords
This publication has 17 references indexed in Scilit:
- Gemcitabine: a promising new agent in the treatment of advanced urothelial cancer.Journal of Clinical Oncology, 1997
- Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer.Journal of Clinical Oncology, 1997
- Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.Journal of Clinical Oncology, 1997
- Gemcitabine in patients with advanced malignant melanoma or gastric cancer: Phase II studies of the EORTC Early Clinical Trials GroupAnnals of Oncology, 1994
- Analytical Methods Validation: Bioavailability, Bioequivalence, and Pharmacokinetic StudiesJournal of Pharmaceutical Sciences, 1992
- A phase I clinical, plasma, and cellular pharmacology study of gemcitabine.Journal of Clinical Oncology, 1991
- Changes in the clearance of total and unbound etoposide in patients with liver dysfunction.Journal of Clinical Oncology, 1990
- Carboplatin dosage: prospective evaluation of a simple formula based on renal function.Journal of Clinical Oncology, 1989
- A program package for simulation and parameter estimation in pharmacokinetic systemsComputer Programs in Biomedicine, 1979
- A new look at the statistical model identificationIEEE Transactions on Automatic Control, 1974